The Strategic Glance

For the first time, luxury automakers offer no satisfaction edge over mass-market brands. A new study reveals how affordability and the quiet rise of hybrids are redrawing the map of consumer desire.

Amid national debates on college value, a partnership between SFSU and 10,000 Degrees offers 300 students guaranteed admission, creating a powerful new model.

Dogwood Therapeutics hits a critical trial milestone for its non-opioid pain drug, signaling a potential breakthrough for millions of cancer survivors.

Hingham Savings posts huge GAAP profits, but the real story is its core operational strength. A deep dive into its funding strategy, tech overhaul, and D.C. real estate management.

Valero's steady $1.20 dividend isn't just good news for investors. It's a sign of robust health in both traditional refining and its growing low-carbon ventures.

A new AI platform is challenging job market titans with free premium tools and resume-based matching. But can its disruptive model sustain its explosive growth?

Gausium is now the world's #1 cleaning robot supplier. This isn't just about automation; it's a strategic blueprint for scalable, intelligent operations.

Millions face overwhelming IRS debt, often misled by false promises of relief. A new book by an Enrolled Agent offers a practical, strategic roadmap.

Recent e-rickshaw hacks in India left drivers stranded and exposed a critical flaw in EV security. A fintech startup's unique payment system, designed to secure loans, accidentally created a fortress against such digital attacks.

With a fresh $150M, Mighty Therapeutics is set to expand its groundbreaking mitochondrial drugs from rare diseases to major conditions like Parkinson's.

With the strategic hire of top-rated analyst Garik Shmois, D.A. Davidson signals a major push to dominate research in the critical construction sector.

A landmark public-private partnership in Vietnam pioneers bioengineered corneas, promising to restore sight to millions and signaling a new era for ASEAN biotech.

In a major corporate governance showdown, all three top proxy advisory firms have sided with Genesco's board, validating its strategy and rebuffing activist Bradley Radoff.

Rubicon Point Partners' acquisition of Wolfe Square isn't just a transaction; it's a strategic move betting on proximity, community, and a new tenant experience.

Backed by $180M, Celea Therapeutics is deploying a bold head-to-head superiority trial, aiming to prove its drug isn't just an alternative but a new standard.

With a newly expanded $225M ABL facility, DXP Enterprises is not just shoring up finances; it's priming the engine for major acquisitions and market expansion.

Beyond its TIME award, AWR's 71-year dividend growth reveals a deeper story of strategic discipline balancing shareholder, employee, and ESG demands.

A new outlet, News.cx, launches with a bold promise: free, concise news to fight fatigue. But can this strategy succeed in a market defined by distrust?

Ashok Soota's Happiest Health is betting on a tech-infused, 'away-from-hospital' model. Can its new Bengaluru clinics redefine urban healthcare?

A historic bipartisan bill to fight organized cargo crime lands in the Senate as industry leaders warn of a crisis costing the U.S. economy up to $35 billion.